InSilico Medicine Overview
- Year Founded
-
2014
- Status
-
IPO Registration
- Employees
-
356
- Latest Deal Type
-
IPO
- (Announced)
- Latest Deal Amount
-
$200M
- Investors
-
42
InSilico Medicine General Information
Description
Researcher and developer of an artificial intelligence (AI) platform and new drugs designed to deliver breakthrough solutions for cancer, fibrosis, immunity, central nervous system diseases and age-related diseases. The company's platform and drugs leverage next-generation AI systems that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques to discover novel targets, design novel molecular structures with desired properties and connect biology, chemistry, and clinical trials analysis, enabling pharmaceutical and academic partners to reduce the time and costs associated with bringing life-saving medications to patients.
Contact Information
Website
www.insilico.comCorporate Office
- Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park
- Pak Shek Kok, New Territories
- Hong Kong
- Hong Kong
Corporate Office
- Unit 310, 3/F, Building 8W, Phase 2, Hong Kong Science Park
- Pak Shek Kok, New Territories
- Hong Kong
- Hong Kong
InSilico Medicine Timeline
InSilico Medicine Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. IPO | 27-Jun-2023 | $200M | 00000 | Announced | Generating Revenue | |
| 11. Later Stage VC (Series D) | 21-Jul-2022 | 0000 | 00000 | 00000 | Completed | Generating Revenue |
| 10. Later Stage VC (Series C1) | 10-Jan-2022 | 0000 | 00000 | 00000 | Completed | Generating Revenue |
| 9. IPO | 08-Nov-2021 | 00000 | Cancelled | Generating Revenue | ||
| 8. Later Stage VC (Series C) | 01-Jun-2021 | 00000 | 00000 | 00000 | Completed | Generating Revenue |
| 7. Later Stage VC (Series B1) | 01-Jan-2020 | 000.00 | 00000 | Completed | Pre-Clinical Trials | |
| 6. Later Stage VC (Series B) | 12-Aug-2019 | 0000 | 000.00 | 00000 | Completed | Pre-Clinical Trials |
| 5. Early Stage VC (Series A3) | 18-Jun-2018 | 000 | 000.00 | 0000 | Completed | Pre-Clinical Trials |
| 4. Early Stage VC (Series A2) | 18-Jul-2017 | $4M | $19.5M | Completed | Pre-Clinical Trials | |
| 3. Early Stage VC (Series A1) | 27-Feb-2017 | $2.8M | $15.5M | Completed | Pre-Clinical Trials |
InSilico Medicine Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 000 |
InSilico Medicine Comparisons
Industry
Financing
Details
000000
00000
InSilico Medicine Competitors (28)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DyNAbind | Venture Capital-Backed | Dresden, Germany | 0 | 000000000 | ||
| Verge Genomics | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 0000000000 0 | 00000 |
| Sygnature Discovery | Private Equity-Backed | Nottingham, United Kingdom | 0000 | 000000000 - | ||
| Cyrus Biotechnology | Venture Capital-Backed | Seattle, WA | 00 | 000.00 | 00000000000 | 000.00 |
| Atomwise | Venture Capital-Backed | San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
InSilico Medicine Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
InSilico Medicine Patents
InSilico Medicine Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240166608-A1 | Tead inhibitors and methods of uses thereof | Pending | 29-Sep-2022 | 0000000000 | |
| US-20230183210-A1 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof | Active | 12-Nov-2021 | 000000000 | |
| US-11739077-B2 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof | Active | 12-Nov-2021 | 000000000 | 00 |
| US-20240190839-A1 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof | Pending | 12-Nov-2021 | 000000000 | |
| US-11731944-B2 | Sars-cov-2 inhibitors for treating coronavirus infections | Active | 02-Nov-2021 | C07D233/96 | 00 |
InSilico Medicine Executive Team (12)
| Name | Title | Board Seat |
|---|---|---|
| Feng Ren Ph.D | Co-Chief Executive Officer, Executive Director & Chief Scientific Officer | |
| Alexander Zhavoronkov Ph.D | Co-Founder, Chief Executive Officer, Executive Director & Chairman | |
| Alexander Aliper Ph.D | Co-Founder & President | |
| Petrina Kamya Ph.D | Head of AI Platforms & President, Canada | |
| Qingsong Zhu Ph.D | General Manager & Secretary |
InSilico Medicine Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alexander Zhavoronkov Ph.D | InSilico Medicine | Co-Founder, Chief Executive Officer, Executive Director & Chairman | 000 0000 |
| Kan Chen Ph.D | Qiming Venture Partners | Board Member | 000 0000 |
| Min Fang | Warburg Pincus | Board Member | 000 0000 |
| Nisa Leung | Qiming Venture Partners | Board Member | 000 0000 |
InSilico Medicine Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
InSilico Medicine Investors (42)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aramco Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |
| BHR Partners | PE/Buyout | Minority | 000 0000 | 000000 0 |
| Boston Investments | Real Estate | Minority | 000 0000 | 000000 0 |
| Ericsenz Capital | PE/Buyout | Minority | 000 0000 | 000000 0 |
| Fong Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 |
InSilico Medicine Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Napa Therapeutics | 14-Aug-2018 | 00000 0000 | Biotechnology | ||
| Consortium.AI | 19-Jul-2018 | 00000 0000 | Other Healthcare Technology Systems | 000000000 | |
| Juvenescence AI | 26-Jul-2017 | Joint Venture | Drug Discovery | 000000000 |
InSilico Medicine FAQs
-
When was InSilico Medicine founded?
InSilico Medicine was founded in 2014.
-
Who is the founder of InSilico Medicine?
Alexander Zhavoronkov Ph.D and Alexander Aliper Ph.D are the founders of InSilico Medicine.
-
Who is the CEO of InSilico Medicine?
Feng Ren Ph.D and Alexander Zhavoronkov Ph.D are the CEOs of InSilico Medicine.
-
Where is InSilico Medicine headquartered?
InSilico Medicine is headquartered in Hong Kong, Hong Kong.
-
What is the size of InSilico Medicine?
InSilico Medicine has 356 total employees.
-
What industry is InSilico Medicine in?
InSilico Medicine’s primary industry is Drug Discovery.
-
Is InSilico Medicine a private or public company?
InSilico Medicine is a Private company.
-
What is InSilico Medicine’s current revenue?
The current revenue for InSilico Medicine is 000000.
-
How much funding has InSilico Medicine raised over time?
InSilico Medicine has raised $428M.
-
Who are InSilico Medicine’s investors?
Aramco Ventures, BHR Partners, Boston Investments, Ericsenz Capital, and Fong Capital Partners are 5 of 42 investors who have invested in InSilico Medicine.
-
Who are InSilico Medicine’s competitors?
DyNAbind, Verge Genomics, Sygnature Discovery, Cyrus Biotechnology, and Atomwise are some of the 28 competitors of InSilico Medicine.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
